Please login to the form below
Schering-Plough
This page shows the latest Schering-Plough news and features for those working in and with pharma, biotech and healthcare.
Organon buys Forendo in $1bn deal
The name comes from the company it acquired as part of its 2009 deal to buy Schering-Plough.
Latest news
-
Hudson named Brandicourt’s successor as Sanofi’s CEO
with 28 years’ experience at big pharma companies including Schering-Plough, AstraZeneca and Novartis.
-
Merck exec steps down, two takes his place
Schechter initially joined the company back in 1988, and also played a key role in the Merck and Schering-Plough $41bn merger in 2009.
-
Standing out in a crowd
Schering-Plough and local Korean pharma companies.
-
Merck faces another Bridion knockback
Bridion was acquired by Merck when it took over Schering-Plough in 2009.
-
SEC calls for greater disclosure from pharma
He cited cases involving Pfizer, Eli Lilly and Schering-Plough (now part of Merck &Co) as US-based examples, and noted that the best way to avoid these violations is through
More from news
Approximately 1 fully matching, plus 150 partially matching documents found.
Latest Intelligence
-
A rare talent
It's something that Sebastian's early roles certainly provided.After an academic start, he had a year-long stint as a sales rep in London for Schering-Plough moving quickly
-
Deal Watch July 2016
And Finally, Reality Bites. ALK-Abello has issued a press release announcing that Merck &Co has walked away from the deal agreed in 2007 (with Schering-Plough) for the allergy treatments
-
Rise of generics will curb France’s pharma growth
Sanofi, Schering-Plough (wholly owned by MSD since 2009) and Janssen are among the companies the French Competition Authority (FCA) has launched enquiries into for this over the last few years.
-
Lonafarnib: promising results in first-ever trial for progeria
Ground-breaking results for lonafarnib. Lonafarnib (Sarasar) is an orally active FTI under clinical development with Schering-Plough (now Merck &Co) in capsule formulation for the treatment of progeria and various ... The open-label study was also led by
-
Interview: Deepak Khanna, ABPI
In his previous role, Deepak was senior vice president and general manager of Merck/Schering-Plough Pharmaceuticals. ... companies. After the announcement of plans to merge with Schering-Plough (March 2009), Deepak also led the US integration planning
More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Sue Mahony to retire as president of Lilly Oncology
Prior to her time with Eli Lilly, Mahony has served in various roles for Amgen, Bristol-Myers Squibb and Schering-Plough.
-
Axovant poaches Allergan’s and Teva’s chief medical and science officers
Throughout his career he has served in numerous roles for Celgene, Amgen, Schering-Plough and Bayer.
-
Astellas promotes Anthony Fiordaliso to VP, Americas finance
He first joined the pharma firm in 2010 from Schering-Plough. Astellas has promoted Anthony Fiodaliso to VP, Americas finance to oversee areas such as managerial reporting and budgeting, financial planning ... He has been with the pharma company since
-
Novartis Oncology head Bruno Strigini to retire
Prior to that he served in a similar role at Schering-Plough, before its acquisition by Merck in 2009.
-
Helen Parfitt joins Research Partnership
coverage. Mark Jeffery, founding director of Research Partnership, said: “Helen brings with her a wealth of knowledge and expertise, her experience at GSK and Schering-Plough means she has also developed
More from appointments
Approximately 0 fully matching, plus 33 partially matching documents found.
Latest from PMHub
-
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Flexibility can be crucial to an effective strategic approach.Olav points to the acquisition of Schering-Plough by Merck as an example of the hidden rewards of taking an elastic perspective ... In 2009, Merck bought its rival Schering-Plough for $41.1bn
-
Research Partnership appoints Helen Parfitt as Director, Head of Therapy Watch
Helen brings with her extensive and wide ranging pharmaceutical and management experience including roles at GlaxoSmithKline and Schering-Plough where she was a Product Manager. ... Helen brings with her a wealth of knowledge and expertise. Her
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
Create Health
A specialist Advertising and Med Comms agency dedicated to bringing much-needed creativity to healthcare marketing. We believe that brilliant ideas...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
